Abstract
Intravenous amphotericin B (AmB) is the most potent drug for treatment of systemic fungal infections in leukemic patients. However, use of this drug is often limited by renal side effects and acute toxicity (fever, chills, nausea, vomiting). A far better tolerance has been reported with the use of AmBisome, a liposomal preparation of AmB, but this formulation is extremely expensive. In search of a cheaper AmB preparation with a better tolerance than conventional AmB, french scientists recently reported that AmB mixed in fat emulsion (Intralipid) has a significantly better tolerance profile compared to conventional AmB (Caillot et al., 1992, Chavanet et al., 1992). Our pilot study was performed to get information about the tolerance of the three different AmB preparations in individual patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
